Key area Cancer Drugs

Our challenge

There have been significant advances in medical treatment of cancer in the past decades, however, access to new cancer drugs remains a challenge. Timely access to products with proven benefit should be assured for patients who need them.

Our dream

To make all forms of cancer treatable with medicines that remain accessible, available, and affordable for everyone.

Our activities

We operate in 7 focus areas, each with specific activities (e.g. research funding, lobby and collaboration).

Academic Drug Development
Medicines originating from academic laboratories reach patients faster—via commercial pathways or fully academic routes.

Research: PIPELINE call, TIL registration, DARE-NL, collaboration with the Center for Drug Development (CDD)
Lobby: in collaboration with the European Cancer League

Repurposing
Existing medicines are used optimally across the entire lifecycle, so every person with cancer has a treatment option.

Research: ATTRACT call, DRUP
Lobby

BRIDGE
We stimulate a behavioral shift so clinical relevance guides model selection and experimental design in preclinical research.

Research: BOOST call

Radiopharmaceuticals
We aim for an optimized public–private ecosystem for radiopharmaceuticals, ensuring sustained patient access at affordable cost.

Activities in development

Molecular Diagnostics
We stimulate the use of molecular diagnostics for personalized treatment.

Activities in development.

Targeted Use
We aim to speed up access to innovative medicines as soon as possible after market authorization, at optimal dosing, while keeping oncology drug costs manageable.

Research: MedACT
Lobby

Access to Medicine
Expose systemic opportunities to keep oncology drug prices manageable and create positive incentives for societally acceptable pricing.